We investigated whether central hemodynamics predict major adverse cardiovascular events (MACEs) in erectile dysfunction (ED) patients beyond traditional risk factors.
Erectile dysfunction (ED) is a highly prevalent disorder that affects, to a varying severity, almost one out of 2 men aged 40-70 years. 1 ED is common in patients with subclinical or symptomatic coronary artery disease (CAD). 2 Importantly, ED is considered an early manifestation of a generalized vascular disease 3 and predicts all-cause mortality and cardiovascular (CV) events including CAD, stroke, and peripheral artery disease. 4 Therefore, within the context of the collectively increased risk that ED confers, identification of those ED patients who are truly at high risk for future CV events has the potential to reduce their risk through lifestyle modification or pharmacological interventions targeted at management of both risk factors and the disease itself. 5 Established and novel biomarkers are particularly useful in primary or secondary prevention, 6 and since ED is primarily a vascular disease, arterial biomarkers are particularly appealing. Several considerations support a mechanistic role for central pressure profiles as causal determinants of CV disease (CVD). 7, 8 The aortic pressure profile is determined by the interactions between the left ventricle and the load imposed by the arterial tree. 7 Wave reflections arising in peripheral arteries and returning to the proximal aorta during mid-to-late systole are important determinants of left ventricle afterload. Central hemodynamics independently predict CV events 9 and have emerged as a potential target for intervention and improvement of patient outcome. 10 The predictive role of central hemodynamics has not been investigated in ED patients. Given the adverse impact of central hemodynamics on outcomes and the large public health burden of ED and CVD, further data regarding the association between central hemodynamics and CV outcomes are needed. Accordingly, we sought to investigate whether central hemodynamics predict CV events in patients with ED and whether such ability is independent of classic risk factors. An important aim of our investigation was to evaluate the risk discrimination and reclassification of these vascular markers, a feature of principal clinical importance.
METHODS

Study population
From January 2004 to June 2014, we enrolled consecutive patients who were referred to the Cardiovascular Diseases and Sexual Health Unit of our Department. These patients had ED symptoms of recent onset but they were neither symptomatic of CVD nor had they documented CVD disease. These patients were evaluated comprehensively with noninvasive tests (exercise stress test and stress echocardiography: 69 (14%) had positive one or both of the 2 noninvasive procedures) and coronary angiography, when indicated, to reveal occult CAD (62/496, 12.5% proved to have CAD). Initially, 496 men were assessed for inclusion in the study. All patients with angiographically documented CAD at onset and 36 men who were lost to follow up were excluded from the study. Finally, 398 men were analyzed.
Hypertension, dyslipidemia, and diabetes mellitus were defined according to established diagnostic criteria or if the subject was taking any medication for these diseases. 11 Patients with malignancy, overt endocrine disease, and use of steroid hormones were also excluded, because these conditions may have a significant influence on both plasma sex hormones and clinical outcome.
Evaluation of ED
ED of vasculogenic origin was diagnosed according to (i) comprehensive medical and sexual history, (ii) score of the 5-item form of the International Index of Erectile Function, the Sexual Health Inventory for Men (SHIM score, ≤21 indicates ED), 12 (iii) comprehensive medical examination (performed by cardiologists, urologists, psychotherapists, and allied-health professionals), (iv) hormonal testing (total testosterone and prolactin), and (v) dynamic penile Doppler ultrasound (with intracavernous injection of alprostadil). Through these evaluations, patients were excluded if their ED was secondary to hormonal, psychological, neurological, or anatomic abnormalities, pelvic surgery, or trauma. Vasculogenic ED is diagnosed when the peak systolic velocity is <35 cm/s, and/or when the end-diastolic velocity is >5 cm/s. 13 
Measurement of central hemodynamics
The peripheral pulse wave was recorded from the radial artery using applanation tonometry. The radial pulse wave was transformed into the central pulse wave of the aorta through analysis of pulse wave with the SphygmoCor device (SphygmoCor, AtCor Medical, Sydney, Australia). 7, 8 Aortic systolic, diastolic, mean, and pulse pressures (PPs) were estimated according to peripheral blood pressures after central wave transformation. 8 While to analyze wave reflections wave separation analysis (aortic pressure wave separation into its forward and reflected components using central pressure and flow waveforms recordings) is recommended and we did not employ in our study, augmentation index (AIx, the ratio of the second minus first systolic pressure divided by PP in the aortic waveform) is influenced by wave reflections and is predictive of hard CV endpoints and target-organ damage. 6, 14 All measurements were conducted in the morning, with the individual in the supine position, in a quiet environment. Participants were requested to abstain from tobacco, coffee, and food at least 5 hours and from alcohol 12 hours before the examination.
Follow-up
Information on major adverse cardiac events (MACEs) up to February 2016 was obtained by visits to our Unit, phone interview, and/or mail. Each subject or a family member completed the questionnaire on MACEs, current medication, and health status. MACEs analyzed as the endpoints of this study included CV death, CAD, stroke, and peripheral arterial disease. All MACEs were validated by research doctors who were unaware of the patient's history and central hemodynamics analysis data, by using death certificates, hospital record forms and interviews.
Statistical analysis
We assessed differences in normal variables by the Student t-test and differences in nonnormal variables by the MannWhitney U test. The Pearson chi-square test was used for frequency comparison. Free of MACE survival among tertiles was estimated by Kaplan-Meier curves and compared by the Mantel log-rank test. For peripheral and central pressures, we calculated relative risks (RRs) per 10-mm Hg difference. For AIx, we calculated RRs per absolute 10% difference. For peripheral pressures, all risk estimates were adjusted for age, heart rate, and risk factors (total cholesterol and smoking). For central pressures and AIx, all risk estimates were adjusted for age, peripheral pressure, heart rate, and risk factors. The robustness of the estimated hazard ratios was evaluated using bootstrap resampling method of 1,000 datasets. Model discrimination was assessed with the Harrel's c-index (which is analogous to the area under the receiver-operator characteristic curve). Calibration was assessed with the Hosmer-Lemeshow test. Improvements in subject reclassification was further assessed using the net reclassification improvement (NRI), which depends on the increased probability that a new model will categorize case subjects as higher risk and decreased probability that it will categorize control subjects as lower-risk, compared to a base model. 15 We computed 2 versions of the NRI: an NRI based on usual categories for 10-year coronary heart disease risk (adapted at 6.5 years). We then computed category-free reclassification measures, which are independent on arbitrarily defined risk thresholds. These include the integrated discrimination improvement (IDI), which expresses the relative improvement in discrimination slopes (difference in mean predicted probabilities between case and control participants) between the base model and new model. Data analysis was performed with SPSS software, version 18.0 (Chicago, IL) and MedCalc statistical software, version 11.5.1 (Mariakerke, Belgium).
RESULTS
Population clinical and MACE characteristics
The mean follow-up time was 6.5 years (range, 1-11), during which 29 (7.2%) subjects developed MACE (24 nonfatal, 5 fatal). Of those with CAD events (n = 20), 2 were CAD deaths, 4 were ST elevation myocardial infarction, and 14 were non-ST elevation myocardial infarction or unstable angina. Four patients with MACE had heart failure symptoms and echocardiographically documented reduced ejection fraction. Other MACE events were cerebrovascular events (n = 6), and new onset of peripheral arterial disease (n = 3, 1 fatal). Table 1 shows the clinical characteristics of ED patients with and without MACE. Compared to patients who did not experience MACE, subjects who developed MACE were older (P < 0.001). The prevalence of arterial hypertension and the prevalence of patients treated with antihypertensive drugs were greater in patients with MACE compared to men who did not experience a MACE (83% vs. 48%, P < 0.001 and 69% vs. 42%, respectively, P = 0.005). All other risk factors are similar between the 2 groups. The percentage of ED patients treated with beta-blockers was not significantly different among patients with, compared to those without MACE (P = 0.31). Total testosterone levels were lower in patients with MACE compared to subjects without MACE (P < 0.05).
Regarding brachial and aortic pressures and AIx, men who developed MACE had higher brachial systolic (P = 0.008) and PP (P < 0.001), as well as higher aortic systolic and PP (all P < 0.001) ( Table 2 ). Patients with MACE had also higher AIx compared to subjects without MACE (all P < 0.001). Heart rate, mean and diastolic (both brachial and aortic) pressures were not different between the 2 groups.
Outcome and prognostic impact of aortic pressures and AIx
Kaplan-Meier analysis. The whole population was divided into tertiles according to the brachial and aortic BP level and AIx. Kaplan-Meier survival curves for MACEs by tertiles of AIx, aortic systolic, and PP at baseline are illustrated in Figure 1 . Aortic systolic, aortic PP, and AIx are significantly associated with MACEs and the differences between the relevant tertiles were significant (all P < 0.01). Kaplan-Meier analysis also revealed a significant association between brachial PP tertiles and MACEs (log-rank: 8.51, P = 0.02) and a nonsignificant association between both brachial and aortic systolic pressure tertiles and MACEs (log-rank: 4.08, P = 0.25 and log-rank: 4.99, P = 0.10, respectively).
Cox-regression analysis. Table 3 shows RR (and significance levels) for MACE for listed parameters after adjustment for age, cholesterol, heart rate, and smoking history 372 ) for a 10% absolute increase of AIx (P = 0.010). The abovementioned associations remained statistically significant even after adding b-blocker use as a covariate in the analysis (all P < 0.05). In contrast with aortic systolic and PP, aortic diastolic pressure was not predictive of outcome in this cohort. By using tertiles in multivariate Cox models, subjects at the highest tertiles, but not those in the middle tertile, had statistically significant RR for MACE compared to those with the lowest tertiles ( Table 4 ). After adjustment for the abovementioned risk parameters, the highest tertiles of aortic PP (>42 mm Hg) and AIx (>31.5%), independently predicted MACEs (RRs: 2.76 and 2.84, respectively), compared with those in the lowest tertiles (<34 mm Hg and <23%, respectively), (all P < 0.05). Including testosterone levels in the multivariate Cox-regression models had only a minor effect on the parameter estimates of AIx and PP without changing the overall conclusions (data not shown). The bootstrap procedure showed that the bias of the RR as regards the brachial and aortic pressure parameters and AIx was very low, indicating robustness of the estimated RR. Reclassification. The incremental utility of aortic pressures (systolic and PP) and AIx added to the FRS with the category-based NRI and IDI are shown in Supplementary Appendix (Table 5a-c) .
Aortic PP significantly improved reclassification for the primary end point as assessed by IDI (0.0060; P = 0.036). The addition of aortic PP resulted in upward reclassification of 3.4% of patients who experienced an event and a downward reclassification of 3.8% of patients who did not experience an event, yielding an indicative category-based NRI of 7.2% (P = 0.20). Including aortic systolic pressure in the multivariate regression models showed a nonsignificant IDI (0.0014, P = 0.18) and NRI (0.2%).
AIx significantly improved reclassification for the primary end point as assessed by IDI (0.0069; P = 0.024). The addition of AIx resulted in upward reclassification of 10.3% of patients who experienced an event and a downward reclassification of 5.4% of patients who did not experience an event, yielding a marginally significant category-based NRI of 15.7% (P = 0.12). Continuous variables, as mean ± SD. Abbreviations: BP, blood pressure; MACE, major adverse cardiovascular events.
*P value refers to differences between patients with a MACE and subjects without MACE.
DISCUSSION
Our study is the first to investigate the prognostic role of central hemodynamics in middle-aged individuals with ED. The principal finding is that aortic systolic and PP and aortic AIx independently of age and risk factors predicted MACEs. Also, risk reclassification in identifying MACE is improved by AIx and aortic PP as assessed by the integrated discrimination index. Given the evidence of the association between ED and adverse CV events, the present finding may suggest that part of this effect could be mediated through the increased central hemodynamics.
Clinical implications
Previous studies implicate increased aortic stiffness in the pathogenesis of CVD in men with ED, 16 but this is the first study to assess the association of central hemodynamics with the risk of MACEs in this population. The clinical implications of our findings stem from the high prevalence of ED across ages 1 from the association of ED with occult CAD 2, 17 and from the independent risk for future CV events that ED carries. 4 Identification of those ED patients who are truly at high risk for future CV events is of paramount importance. Such patients may require a comprehensive evaluation to reveal occult CAD and are candidates of aggressive management of the risk factors to reduce their CV disease risk and concomitantly improve their sexual function. 5, 18 Finally, vasoactive drugs such as phosphodiesterase-5 (PDE-5) inhibitors strongly decrease wave reflections. 19 This is important taking into consideration that treatment of ED itself by PDE-5 inhibitors may also reduce CV disease risk. 20 Therefore, our findings not only have implications for CVD risk assessment but may also identify a potential novel therapeutic target for CVD prevention in these patients. However, the purpose of this study was not to specifically investigate whether PDE-5 inhibition is therapeutic strategy directly targeted to the reduction of CVD risk; thus, this issue must be addressed in appropriately designed clinical trials.
Central hemodynamincs and CV risk
Central hemodynamics are predictive of composite CVD endpoints. 6, 9 This predictive ability is more consistent in populations with manifest CV or renal disease, and less so in the general population. 9 The setting of ED can be viewed as an "in-between" situation both at pathophysiological and clinical levels. In our study, the adjusted relationship between AIx/aortic PP and incident MACEs was consistent. A particular strength of our study is the stringent tests that we used to validate central pressures and AIx, such as the IDI; adding AIx and aortic PP to the models led to a statistically significant improvement in the IDI which is a categoryfree reclassification measure. Therefore, central pressures and AIx fulfill important criteria for a biomarker to enter the clinical arena as regards investigation of ED patients without known CVD.
Although central hemodynamics are influenced by age (principally) and by other traditional risk factors (less so), 21 the predictive ability of central pressures and AIx is independent of these parameters. This is particularly important because CAD and ED share many risk factors such as age, hypertension, diabetes mellitus, hyperlipidemia, and smoking. 22 Furthermore, although most studies have shown that ED predicts CV risk independently of risk factors, 4 this has been questioned. The fact that the predictive ability of central hemodynamics and aortic stiffness are independent of classic risk factors implies that the risk that ED carries for future CV events is on top of that conferred by these factors.
Mechanisms
Association of central hemodynamics with increased risk of MACE in patients with ED can be attributed to a faster return of reflected waves (due to increased pulse wave velocity resulting from stiffer large arteries) and/or the increase in the magnitude of the incident waves that are reflected at the periphery. 7 While the first mechanism has been demonstrated in the setting of ED, 16 the latter can only be indirectly substantiated. Increased peripheral vasoconstriction determines a greater amount of the incident wave to be reflected at the periphery. Endothelial dysfunction that may be related to peripheral vasoconstriction is a major pathophysiological mechanism underlying vasculogenic ED. 23, 24 Increased arterial stiffening and endothelial dysfunction can be associated with inflammatory activation and testosterone depletion. [25] [26] [27] Both the latter conditions are strongly related to vasculogenic ED. [28] [29] [30] Nevertheless, further studies are needed to elucidate these possible underlying mechanisms.
Limitations
Our observational study cannot prove a causal link between central hemodynamics and MACE. Another limitation of our study is the nonavailability of data regarding physical activity, which has been shown by some studies to be significantly correlated with wave reflection changes. 31 There is a strong association between wave reflections and incident CV events and heart failure in the general population 32 ; however, the relatively small number of ED patients with heart failure in our population did not permit us to investigate such an association. Finally, it would be desirable to replicate our findings in larger populations to better establish their generalizability.
In conclusion, while the presence of ED per se increases CV risk it is also important to determine within ED which patients are at higher risk. A growing body of evidence supports the potential use of a number of easily measured vascular or circulating biomarkers to further characterize risk for CV events in men with ED, but few have been evaluated in this population. The findings of our study demonstrate a consistent, adjusted for age and risk factors, relationship between AIx/aortic PP and incident MACEs. These biomarkers fulfill important criteria to enter the clinical arena as regards investigation of ED patients without known CVD. Further studies are needed to assess whether aortic pressures and AIx when used a treatment target can reduce further CV risk in the context of ED.
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